EFFETTO DELLA VILOXAZINA SUI LIVELLI EMATICI DI OXCARBAZEPINA E DEI RELATIVI METABOLITI

F. Pisani; A. Fazio; C. Artesi; M. Russo; R. Trio; G. Oteri; B. Xiao; E. Perucca; R. Di Perri

EFFETTO DELLA VILOXAZINA SUI LIVELLI EMATICI DI OXCARBAZEPINA E DEI RELATIVI METABOLITI

Translated title of the contribution: The effect of viloxazine on the serum levels of Oxcarbazepine and its metabolites

F. Pisani, A. Fazio, C. Artesi, M. Russo, R. Trio, G. Oteri, B. Xiao, E. Perucca, R. Di Perri

Fondazione "Istituto Neurologico Casimiro Mondino"

Research output: Contribution to journal › Article › peer-review

Abstract

Addition of the antidepressant drug Viloxazine (VLX) to six epileptic patients stabilized on oxcarbazepine (OXCZ) therapy was evaluated with respect to serum levels of OXCZ and its two major metabolites MHD and DHD. The study was carried out in a randomized, double-blind, placebo-controlled design. Administration of VLX resulted in an increase in MHD levels by 11% on average and a concomitant decrease in plasma DHD by 31% on average. Steady-state levels of OXCZ remained stable throughout the study. These changes in plasma OXCZ metabolites were not associated with clinical manifestations.

Translated title of the contribution	The effect of viloxazine on the serum levels of Oxcarbazepine and its metabolites
Original language	Italian
Pages (from-to)	157-158
Number of pages	2
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	82-83
Publication status	Published - 1993

ASJC Scopus subject areas

Clinical Neurology

Fingerprint Dive into the research topics of 'The effect of viloxazine on the serum levels of Oxcarbazepine and its metabolites'. Together they form a unique fingerprint.

Cite this

@article{88a7c8bd99684aafa43c084c9e84fd85,

title = "EFFETTO DELLA VILOXAZINA SUI LIVELLI EMATICI DI OXCARBAZEPINA E DEI RELATIVI METABOLITI",

abstract = "Addition of the antidepressant drug Viloxazine (VLX) to six epileptic patients stabilized on oxcarbazepine (OXCZ) therapy was evaluated with respect to serum levels of OXCZ and its two major metabolites MHD and DHD. The study was carried out in a randomized, double-blind, placebo-controlled design. Administration of VLX resulted in an increase in MHD levels by 11% on average and a concomitant decrease in plasma DHD by 31% on average. Steady-state levels of OXCZ remained stable throughout the study. These changes in plasma OXCZ metabolites were not associated with clinical manifestations.",

author = "F. Pisani and A. Fazio and C. Artesi and M. Russo and R. Trio and G. Oteri and B. Xiao and E. Perucca and {Di Perri}, R.",

year = "1993",

language = "Italian",

pages = "157--158",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "82-83",

}

TY - JOUR

T1 - EFFETTO DELLA VILOXAZINA SUI LIVELLI EMATICI DI OXCARBAZEPINA E DEI RELATIVI METABOLITI

AU - Pisani, F.

AU - Fazio, A.

AU - Artesi, C.

AU - Russo, M.

AU - Trio, R.

AU - Oteri, G.

AU - Xiao, B.

AU - Perucca, E.

AU - Di Perri, R.

PY - 1993

Y1 - 1993

N2 - Addition of the antidepressant drug Viloxazine (VLX) to six epileptic patients stabilized on oxcarbazepine (OXCZ) therapy was evaluated with respect to serum levels of OXCZ and its two major metabolites MHD and DHD. The study was carried out in a randomized, double-blind, placebo-controlled design. Administration of VLX resulted in an increase in MHD levels by 11% on average and a concomitant decrease in plasma DHD by 31% on average. Steady-state levels of OXCZ remained stable throughout the study. These changes in plasma OXCZ metabolites were not associated with clinical manifestations.

AB - Addition of the antidepressant drug Viloxazine (VLX) to six epileptic patients stabilized on oxcarbazepine (OXCZ) therapy was evaluated with respect to serum levels of OXCZ and its two major metabolites MHD and DHD. The study was carried out in a randomized, double-blind, placebo-controlled design. Administration of VLX resulted in an increase in MHD levels by 11% on average and a concomitant decrease in plasma DHD by 31% on average. Steady-state levels of OXCZ remained stable throughout the study. These changes in plasma OXCZ metabolites were not associated with clinical manifestations.

UR - http://www.scopus.com/inward/record.url?scp=0027820473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027820473&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0027820473

SP - 157

EP - 158

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 82-83

ER -